Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?

Current Atherosclerosis Reports

Volumn 17, Issue 11, 2015, Pages

  Mitter, Sumeet S ^a   Shah, Sanjiv J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Heart failure with preserved ejection fraction; Mineralocorticoid receptor antagonists; Outcomes; Randomized controlled trial; Spironolactone

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FINERENONE; IRBESARTAN; MINERALOCORTICOID ANTAGONIST; NEBIVOLOL; PERINDOPRIL; PLACEBO; POTASSIUM; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE; VALSARTAN; ALDOSTERONE;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; DRUG EFFICACY; HEALTH CARE COST; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NUMBERS NEEDED TO TREAT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; HEART FAILURE; PATHOPHYSIOLOGY;

ALDOSTERONE; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84942808428     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-015-0541-6     Document Type: Review

References (73)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update: a report from the american heart association. Circulation. 2015;131:e29–322.
2. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(Suppl P):P9–16.
3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.
4. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10:401–10.
5. Andersson C, Vasan RS. Epidemiology of heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10:377–88.
6. Poppe KK, Doughty RN. Outcomes in patients with heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10:503–10.
7. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507–15.
8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.
9. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.
10. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.
11. Flather MD, Shibata MC, Coats A. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–25.
12. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.
13. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.
14. Chan MMY, Lam CSP. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail. 2013;15:604–13.
15. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670–9.
16. Desai AS, Mitchell GF, Fang JC, Creager MA. Central aortic stiffness is increased in patients with heart failure and preserved ejection fraction. J Card Fail. 2009;15:658–64.
17. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144–50.
18. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA. 2008;300:431–3.
19. Kovács Á, Papp Z, Nagy L. Causes and pathophysiology of heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10:389–98.
20. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.
21. Zile MR, Baicu CF, Ikonomidis J, Stroud RE, Nietert PJ, Bradshaw AD, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247–59.
22. Campbell RT, McMurray JJV. Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10:481–501.
23. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50:768–77.
24. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76–84.
25. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–9.
26. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689–97.
27. Edelmann F, Tomaschitz A, Wachter R, Gelbrich G, Knoke M, Düngen H-D, et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J. 2012;33:203–12.
28. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 2001;37:662–7.
29. Bauersachs J, Heck M, Fraccarollo D, Hildemann SK, Ertl G, Wehling M, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39:351–8.
30. Schäfer A, Fraccarollo D, Hildemann SK, Tas P, Ertl G, Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res. 2003;58:655–62.
31. Kimura S, Ito M, Tomita M, Hoyano M, Obata H, Ding L, et al. Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. Hypertens Res. 2011;34:584–91.
32. Kurrelmeyer KM, Ashton Y, Xu J, Nagueh SF, Torre-Amione G, Deswal A. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail. 2014;20:560–8.
33. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–17.
34. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
35. Roongsritong C, Sutthiwan P, Bradley J, Simoni J, Power S, Meyerrose GE. Spironolactone improves diastolic function in the elderly. Clin Cardiol. 2005;28:484–7.
36. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res. 2002;25:837–42.
37. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110:558–65.
38. Edwards NC, Ferro CJ, Kirkwood H, Chue CD, Young AA, Stewart PM, et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol. 2010;106:1505–11.
39. Daniel KR, Wells G, Stewart K, Moore B, Kitzman DW. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail. 2009;15:68–74.
40. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781–91. The Aldo-DHF study was a high-quality randomized controlled trial in generally early-stage HFpEF patients. The trial demonstrated beneficial effects of spironolactone on diastolic function but failed to show improvement in exercise capacity.
41. Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail. 2011;17:634–42.
42. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162:966–72.
43. Shah SJ, Heitner JF, Sweitzer NK, Anand IS, Kim H-Y, Harty B, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6:184–92.
44. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92. The TOPCAT trial was a major randomized controlled trial (n = 3445) of spironolactone versus placebo for HFpEF. Importantly, the TOPCAT trial showed that spironolactone reduces HF hospitalization in patients with HFpEF.
45. Chen Y, Wang H, Lu Y, Huang X, Liao Y, Bin J. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. BMC Med. 2015;13:10.
46. Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2013;1:40–7.
47. Lund LH, Benson L, Dahlström U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308:2108–17.
48. Miller RJH, Howlett JG. Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction. Curr Opin Cardiol. 2015;30:168–72.
49. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) Trial. Circulation. Lippincott Williams Wilkins. 2015;131:34–42. The regional differences sub-study of TOPCAT demonstrated concerning geographic differences in the TOPCAT trial. Based on the results of this study, it appears that many of the patients enrolled in Russia and the Republic of Georgia may not have had HFpEF. Furthermore, the lack of hyperkalemia and increased creatinine in the spironolactone arm in Russia/Georgia may mean that patients in these countries were not receiving the study medication. This study supports the use of spironolactone in HFpEF by showing that in the Americas, spironolactone decreased the primary and secondary endpoints and was nearly associated with a decrease in all-cause mortality.
50. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–51.
51. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. EPHESUS Investigators. Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation. 2008;118:1643–50.
52. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012;60:2082–9.
53. Eschalier R, McMurray JJV, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62:1585–93.
54. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69–78.
55. Pitt B, Køber L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453–63. Finerenone is a novel non-steroidal MRA which appears to be more cardioselective than spironolactone or eplerenone, and therefore may be associated with greater benefits and less adverse effects in patients with HFpEF. This study by Pitt et al. showed that finerenone was equally effective compared to spironolactone and it was associated with a lower incidence of hyperkalemia and worsening renal function.
56. Pitt B, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. Rationale and design of miner alocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17:224–32.
57. Efthimiadis GK, Zegkos T, Karvounis H. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;371:179–80.
58. Kumar N, Garg N. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;371:180.
59. Morawietz H, Bornstein SR. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;371:181.
60. Pfeffer MA, Pitt B, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;371:181–2.
61. Lindman BR, Davila-Roman VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64:541–9.
62. Shah SJ. Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter∗. J Am Coll Cardiol. 2013;62:1339–42.
63. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131:269–79.
64. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
65. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95.
66. Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, et al. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014;7:953–9.
67. Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail. 2014;16:671–7.
68. Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE studies (SOCRATES). Eur J Heart Fail. 2014;16:1026–38.
69. Zakeri R, Levine JA, Koepp GA, Borlaug BA, Chirinos JA, LeWinter M, et al. Nitrate’s effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design. Circ Heart Fail. 2015;8:221–8.
70. Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, et al. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation. 2015;131:371–80.
71. Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62:1330–8.
72. Søndergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail. 2014;16:796–801.
73. Hasenfuss G, Gustafsson F, Kaye D, Shah SJ, Burkhoff D, Reymond M-C, et al. Rationale and design of the reduce elevated left atrial pressure in patients with heart failure (Reduce LAP-HF) trial. J Card Fail. 2015;21:594–600.